MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma

Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, discusses results from the Phase II MAGNOLIA trial (NCT03846427), which evaluated the safety and efficacy of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). Dr Linton highlights the long-term safety data and high overall response rates (ORR) observed with this agent. When compared to pooled data on patients treated with ibrutinib, zanubrutinib demonstrated lower cardiovascular toxicity and was well tolerated, providing a promising novel therapeutic approach for patients with R/R MZL. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.